Related references
Note: Only part of the references are listed.Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes
Aditya A. Wakankar et al.
BIOCONJUGATE CHEMISTRY (2010)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Jagath R. Junutula et al.
CLINICAL CANCER RESEARCH (2010)
Charge heterogeneity of a therapeutic monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin
Eiki Maeda et al.
JOURNAL OF CHROMATOGRAPHY A (2010)
Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy
Sherly Quiles et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Assessing monoclonal antibody product quality attribute criticality through clinical studies
Andrew M. Goetze et al.
MABS (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Novel anti-tubulin cytotoxic agents for breast cancer
Patrick G. Morris et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates
Irwin Hollander et al.
BIOCONJUGATE CHEMISTRY (2008)
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: Impact of assay format on pharmacokinetic parameters determination
Jean-Philippe Stephan et al.
BIOCONJUGATE CHEMISTRY (2008)
Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
J. Vlasak et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Application of imaging capillary IEF for characterization and quantitative analysis of recombinant protein charge heterogeneity
Zoran Sosic et al.
ELECTROPHORESIS (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
J. F. DiJoseph et al.
LEUKEMIA (2007)
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F. McDonagh et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Drug-conjugated monoclonal antibodies for the treatment of cancer
JM Lambert
CURRENT OPINION IN PHARMACOLOGY (2005)
Structural characterization of the maytansinoid -: monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry
LT Wang et al.
PROTEIN SCIENCE (2005)
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
MMC Sun et al.
BIOCONJUGATE CHEMISTRY (2005)
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates
MS Fleming et al.
ANALYTICAL BIOCHEMISTRY (2005)
Non-enzymatic hinge region fragmentation of antibodies in solution
AJ Cordoba et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
AC Lazar et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
Arming antibodies: prospects and challenges for immunoconjugates
AM Wu et al.
NATURE BIOTECHNOLOGY (2005)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery
A Safavy et al.
BIOCONJUGATE CHEMISTRY (2003)
Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains
HD King et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Identification of multiple sources of charge heterogeneity in a recombinant antibody
RJ Harris et al.
JOURNAL OF CHROMATOGRAPHY B (2001)
Share Paper
